MS Badri - Department of Developmental Biology, Faculty of Sciensec andAdvanced Technologies in Biology, University of Science and Culture,Tehran, Iran . Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cel
M Zarghami - Department of Developmental Biology, Faculty of Sciensec andAdvanced Technologies in Biology, University of Science and Culture,Tehran, Iran . Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cel
M SABER - Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cell Biology andTechnology, ACECR, Tehran, Iran
F Shekari - Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cell Biology andTechnology, ACECR, Tehran, Iran
M Ebrahimi - Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cell Biology andTechnology, ACECR, Tehran, Iran
N Hassani - Department of S tem Cells and Developmental Biology, Cell ScienceResearch Center, Royan Ins titute for S tem Cell Biology andTechnology, ACECR, Tehran, Iran

Objective: S tudies on cancer as the second leading cause ofdeath, have been indicated the similarity between pluripotents tem cells (PSCs) and cancer cells in cellular and molecularcharacteris tics. This similarity has led to the hypothesis thatPSCs could be used as tumor antigens and opened new approachesfor the possibility of using PSCs for cancer treatment.Materials and Methods: The human induced pluripotent s temcell line (CAG-hiPSC) was provided from Royan S tem CellBank and cultured. The cells were prepared in lysate form beforevaccination. Cell lysate was prepared after five cycles offreeze-thawing. BALB/C mice were immunized in differentgroups with ۱) hiPSC lysate, ۲) hiPSC lysate+Adj, and ۳) Freundadjuvant (control). After three once-weekly vaccinations,۴T۱ breas t cancer cell line was injected into the mice. Immunologicalanalyzes were performed to inves tigate the immuneresponse in different treatment groups.Results: Immunohis tochemis try (IHC) s taining revealed thatthe expression of CD۸ and CD۴ markers were significantlyhigher in the tumor of hiPSC+Adj-treated mice in comparison tothe Adj-treated mice. Moreover, mice treated with hiPSC+Adjexhibited significantly increased secretion of IFN-γ and IL-۴ incomparison to the Adj-treated mice. There were no significantdifferences in the frequency of IL-۱۰ between hiPSC+Adj andAdj groups.Conclusion: Our findings sugges ted that among all the treatmentstes ted, the combination of hiPSC with Adj could providemore effective immunity in the breas t cancer mouse model byinducing anti-tumor responses

Antitumor Immunity, Cancer Vaccine, Human PluripotentS tem Cells